Edition:
United Kingdom

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

135.22USD
7:29pm GMT
Change (% chg)

$-0.90 (-0.66%)
Prev Close
$136.12
Open
$137.54
Day's High
$137.54
Day's Low
$133.33
Volume
20,255
Avg. Vol
58,393
52-wk High
$154.35
52-wk Low
$13.11

Latest Key Developments (Source: Significant Developments)

Madrigal Pharmaceuticals Prices Public Offering Of Common Stock
Tuesday, 19 Dec 2017 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC SAYS PRICES OFFERING OF 1.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $83.00 PER SHARE.  Full Article

Madrigal Pharma Announces Proposed Public Offering Of Common Stock
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON STOCK​.  Full Article

Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL.MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAS BEEN WELL-TOLERATED WITH MOSTLY MILD AES, AND A FEW MODERATE AES IN STUDY.MADRIGAL PHARMACEUTICALS INC - THERE HAVE BEEN THREE SERIOUS ADVERSE EFFECTS IN STUDY, ALL CONSIDERED UNRELATED TO MGL-3196.MADRIGAL PHARMACEUTICALS - IN TRIAL, MGL-3196 DEMONSTRATED STATISTICALLY SIGNIFICANT RESULTS FOR THE PRIMARY ENDPOINT.  Full Article

Madrigal Pharmaceuticals reports Q3 loss per share of $0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Madrigal Pharmaceuticals Inc :Madrigal Pharmaceuticals reports 2017 third quarter financial results.Qtrly loss per share $0.68 ‍​.‍As of Sept 30, had cash, cash equivalents and marketable securities of $62.1 million, versus $40.5 million at December 31, 2016​.On track to report top-line results for nash late this year and hefh early in 2018​.  Full Article

Rebecca Taub, M.D reports 10.38 pct stake in Madrigal Pharmaceuticals
Monday, 1 Aug 2016 

Madrigal Pharmaceuticals Inc : Rebecca Taub, M.D reports 10.38 pct stake in Madrigal Pharmaceuticals as of July 22, 2016 - SEC Filing Source - http://bit.ly/2auxhO2 Further company coverage: [MDGL.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Paul A. Friedman, M.D. reports 8.25 pct stake in Madrigal Pharmaceuticals
Monday, 1 Aug 2016 

Madrigal Pharmaceuticals Inc : Paul A. Friedman, M.D. reports 8.25 pct stake in Madrigal Pharmaceuticals as of July 22, 2016 - SEC Filing Source - http://bit.ly/2amL8Hp Further company coverage: [MDGL.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Bay City Capital LLC reports 49.9 pct stake in Madrigal Pharmaceuticals - SEC Filing
Friday, 29 Jul 2016 

Madrigal Pharmaceuticals Inc :Bay City Capital LLC reports 49.9 pct stake in Madrigal Pharmaceuticals Inc as of July 22, 2016 - SEC Filing.  Full Article

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)